News
Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...
Germany's Merck KGaA will acquire US biotech firm SpringWorks Therapeutics for $3.9 billion. This strategic move aims to ...
Merck KGaA, Darmstadt, Germany, a science and technology company, has entered into a definitive agreement to acquire ...
Online retailer Temu — owned by PDD Holdings (PDD) — aims to raise prices amid tariffs, while Tesla (TSLA) raises its EV ...
The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity value of ...
So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...
Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback